|
[1]CHOO QL, KUO G, WEINER AJ, et al.Isolation of a c DNA clone derived from a blood-borne non-A, non-B viral hepatitis genome[J].Science, 1989, 244 (4902) :359-362.
|
|
[2]HOOFNAGLE JH.Course and outcome of hepatitis C[J].Hepatology, 2002, 36 (5 Suppl 1) :s21-s29.
|
|
[3]PIETSCHMANN T.Virology:Final entry key for hepatitis C[J].Nature, 2009, 457 (7231) :797-798.
|
|
[4]JIANG XQ, ZOU XJ, TIAN DY.Virological response of chronic hepatitis C treated with peg-interferon a-2a and ribavirin[J].J Clin Hepatol, 2011, 27 (4) :417-419. (in Chinese) 姜雪强, 邹小静, 田德英.聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者的病毒学应答[J].临床肝胆病杂志, 2011, 27 (4) :417-419.
|
|
[5]AFDHAL N, REDDY KR, NELSON DR, et al.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection[J].N Engl J Med, 2014, 370 (16) :1483-1493.
|
|
[6]CHEENT K, KHAKOO SI.Natural killer cells and hepatitis C:action and reaction[J].Gut, 2011, 60 (2) :268-278.
|
|
[7]EDLICH B, AHLENSTIEL G, ZABALETA AZPIROZ A, et al.Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients[J].Hepatology, 2012, 55 (1) :39-48.
|
|
[8]SERTI E, CHEPA-LOTREA X, KIM YJ, et al.Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function[J].Gastroenterology, 2015, 149 (1) :190-200.e192.
|
|
[9]SPAAN M, van OORD G, KREEFFT K, et al.Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment[J].J Infect Dis, 2016, 213 (2) :216-223.
|
|
[10] DUAN ZJ, ZHI YH, LONG L, et al.The frequency, phenotypes and invtiro cytotoxic effects of icrculating CD 56+T cells in the patients with chornic HCV infection[J].Chin J Microbiol Immunol, 2013, 33 (7) :481-487. (in Chinese) 段昭君, 支玉红, 龙璐, 等.慢性HCV感染者外周血中CD56+T细胞频数、表型和体外细胞毒功能研究[J].中华微生物学和免疫学杂志, 2013, 33 (7) :481-487.
|
|
[11]GOLDEN-MASON L, MADRIGAL-ESTEBAS L, MCGRATH E, et al.Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure[J].Gut, 2008, 57 (8) :1121-1128.
|
|
[12]WANG JJ.Study on natural killer cell function in hepatitis C virus infection and antiviral therapy outcome[D].Wuhan:Huazhong University of Science and Technology, 2010.王久君.NK细胞功能与HCV感染及抗病毒治疗转归的研究[D].武汉:华中科技大学, 2010.
|
|
[13]HARRISON RJ, ETTORRE A, LITTLE AM, et al.Association of NKG2A with treatment for chronic hepatitis C virus infection[J].Clin Exp Immunol, 2010, 161 (2) :306-314.
|
|
[14]MERAD M, SATHE P, HELFT J, et al.The dendritic cell lineage:ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting[J].Annu Rev Immunol, 2013, 31:563-604.
|
|
[15]MENGSHOL JA, GOLDEN-MASON L, CASTELBLANCO N, et al.Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus:associations with antiviral treatment outcomes[J].Gut, 2009, 58 (7) :964-973.
|
|
[16]LIANG CC, LIU CH, LIN YL, et al.Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1who failed peginterferon plus ribavirin therapy[J].J Med Virol, 2011, 83 (7) :1212-1220.
|
|
[17]HAMMOND T, LEE S, WATSON MW, et al.Decreased IFNgamma production correlates with diminished production of cytokines by dendritic cells in patients infected with hepatitis C virus and receiving therapy[J].J Viral Hepat, 2011, 18 (7) :482-492.
|
|
[18]KLENERMAN P, THIMME R.T cell responses in hepatitis C:the good, the bad and the unconventional[J].Gut, 2012, 61 (8) :1226-1234.
|
|
[19]SEIGEL B, BENGSCH B, LOHMANN V, et al.Factors that determine the antiviral efficacy of HCV-specific CD8 (+) T cells ex vivo[J].Gastroenterology, 2013, 144 (2) :426-436.
|
|
[20]MARTIN B, HENNECKE N, LOHMANN V, et al.Restoration of HCV-specific CD8+T cell function by interferon-free therapy[J].J Hepatol, 2014, 61 (3) :538-543.
|
|
[21]BARRETT L, SHIVASABESAN G, WANG C, et al.Altered HCV specific T cell immunity very early in interferon free HCV DAA therapy[J].J Hepatol, 2013, 58 (S1) :s1.
|
|
[22]BURCHILL MA, GOLDEN-MASON L, WIND-ROTOLO M, et al.Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals[J].J Viral Hepat, 2015, 22 (12) :983-991.
|
|
[23]SPAAN M, CLAASSEN MA, HOU J, et al.The intrahepatic T cell compartment does not normalize years after therapy-induced hepatitis C virus eradication[J].J Infect Dis, 2015, 212 (3) :386-390.
|
|
[24]LANGHANS B, NISCHALKE HD, KRAMER B, et al.Increased peripheral CD4+regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C[J].J Hepatol, 2017, 66 (5) :888-896.
|
|
[25] REIG M, MARINO Z, PERELLO C, et al.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J].J Hepatol, 2016, 65 (4) :719-726.
|
|
[26]GODFREY DI, ULDRICH AP, MCCLUSKEY J, et al.The burgeoning family of unconventional T cells[J].Nat Immunol, 2015, 16 (11) :1114-1123.
|
|
[27]FRANCISZKIEWICZ K, SALOU M, LEGOUX F, et al.MHC class I-related molecule, MRI, and mucosal-associated invariant T cells[J].Immunol Rev, 2016, 272 (1) :120-138.
|
|
[28]HOFMANN M, THIMME R.MAIT be different-persisting dysfunction after DAA-mediated clearance of chronic hepatitis C virus infection[J].Eur J Immunol, 2016, 46 (9) :2099-2102.
|
|
[29]CARLIN AF, ARISTIZABAL P, SONG Q, et al.Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection[J].Hepatology, 2015, 62 (4) :1047-1058.
|
|
[30]HENGST J, FALK CS, SCHLAPHOFF V, et al.Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C[J].J Infect Dis, 2016, 214 (12) :1965-1974.
|
|
[31]REHERMANN B, BERTOLETTI A.Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections[J].Hepatology, 2015, 61 (2) :712-721.
|
DownLoad: